taletrectinib (Ibtrozi)

Indications

• treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)
  • specifically for patients whose cancer has progressed on prior ROS1 tyrosine kinase inhibitor (TKI) therapy or for those who have not previously received a tyrosine kinase inhibitor

Dosage

• 200 MG Oral Capsule

More general terms

• small inhibitory antineoplastic agent (ib drug)